Transplant News and Research

RSS

Clinical Data expands PGxHealth's FAMILION tests to include two new tests to diagnose heart diseases

Clinical Data, Inc., announced today that its PGxHealth division is expanding its FAMILION family of genetic tests to include two new tests to diagnose heart diseases. With the launch of a test for Conduction Disease associated with Dilated Cardiomyopathy and a test for Short QT Syndrome, PGxHealth continues to lead the industry with the most comprehensive menu of genetic tests to diagnose or confirm familial heart diseases.

12 May 2010

Benefits outweigh risks in myeloablative therapy for children with high-risk neuroblastoma

Neuroblastoma is among the most common of childhood cancers and fortunately, some children will get better spontaneously. Yet for children with high-risk disease the outlook is poor: more than half will relapse despite chemotherapy.

12 May 2010

NY public hospital system plans to lay off about 500 workers and other state news

The Wall Street Journal: "New York City's Health & Hospitals Corp., the nation's largest public hospital system, plans to stanch a $1.2 billion budget gap in the next year's budget by laying off about 500 workers and ending contracts with 'a significant number' of physicians, its president said.

12 May 2010

DUSA Pharmaceuticals first-quarter total product revenues up 22%

DUSA Pharmaceuticals, Inc., a dermatology company that is developing and marketing Levulan Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the first quarter ended March 31, 2010.

11 May 2010

New multicenter trial achieves 71% survival in AML children

More individualized therapy and better supportive care helped push the survival for children with acute myeloid leukemia (AML) to 71 percent three years after diagnosis, according to new research led by St. Jude Children's Research Hospital investigators and reported in the medical journal The Lancet Oncology. The survival rate of 71 percent is 20 percent better than previously reported U.S. rates and is similar to the success achieved in a 2009 Japanese study, said Jeffrey Rubnitz, M.D., Ph.D., a member of the St. Jude Oncology department.

11 May 2010

Increased cholesterol levels can affect microenvironment of bone marrow

Increased cholesterol levels are being increasingly recognised as risk factors for the onset and progression of several cancers. Now researchers in Portugal show that high levels of cholesterol can affect the microenvironment of the bone marrow, so that more cells move from the bone marrow to peripheral, circulating blood.

11 May 2010

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells (ADRCs) for the treatment of no-option chronic heart disease patients showed the following: the procedure was safe and feasible; it demonstrated a statistically significant improvement in maximum oxygen consumption and patients' aerobic capacity measured as metabolic equivalents

10 May 2010

Steroids can raise cardiovascular risks in post-transplant patients

Post-transplant patients who have been removed from a corticosteroid regimen have fewer cardiovascular events than those patients on steroids, increasing their graft survival rates and reducing early mortality, according to study results being presented this week by University of Cincinnati (UC) transplantation researchers.

10 May 2010

Inflammation enzyme regulates production of brown fat tissue

Love handles, muffin tops and stomach tires - white fat tissue forms the typical curves in the notorious problem areas to store energy. Exactly the opposite happens in brown fat tissue: Instead of being stored, energy gets transformed into heat. To the dismay of many people, adults have only small amounts of this energy burner. By contrast, babies and animals in hibernation have lots of it in their bodies where it serves for heat regulation.

7 May 2010

DUSA Pharmaceuticals receives notice of allowance for patent covering blue light technology

DUSA Pharmaceuticals, Inc.®, a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office has issued a notice of allowance for a key patent related to its proprietary PDT light source, the BLU-U®, Blue Light Photodynamic Therapy Illuminator.

7 May 2010

Movements of satellite cells could help patients with muscular dystrophy: MU researchers

When muscle tissue experiences trauma or disease, such as muscular dystrophy, stem cells in the muscle known as "satellite cells" respond to repair and regenerate the muscle. These cells are particularly important in neuromuscular diseases, such as muscular dystrophy, which affect muscle stability and repair.

7 May 2010

Genzyme to initiate $2 billion stock buyback

Genzyme Corp. today announced that its Board of Directors has voted to pursue several actions to increase shareholder value. The company will initiate a $2 billion stock buyback, under which $1 billion of stock will be repurchased in the near term and financed with debt. The additional $1 billion of stock will be repurchased during the next 12 months.

7 May 2010

Cytochroma reports positive results from Phase I trial for CTAP201 Injection in hemodialysis patients

Cytochroma today announced positive Phase I results for CTAP201 Injection, a product being developed to treat secondary hyperparathyroidism in hemodialysis patients. The study demonstrated that single intravenous doses of 1 and 3 mcg of CTAP201 were safe and well tolerated. It also identified a starting dose of 2 mcg for subsequent pivotal trials intended to establish the product's safety and efficacy in the targeted population.

6 May 2010

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010.

6 May 2010

Vical reports net loss of $8.5 million for first-quarter 2010

Vical Incorporated today reported financial results for the quarter ended March 31, 2010. Revenues were $1.5 million for the first quarter of 2010 compared with $2.3 million for the first quarter of 2009, reflecting lower revenues under the company's license agreement with AnGes MG, Inc. Operating expenses were $10.1 million for the first quarter of 2010 compared with $10.6 million for the first quarter of 2009.

6 May 2010

Study confirms long-term durability of endoscopic RFA using HALO system for eradicating Barrett's esophagus

Results from two major multi-center clinical trials presented at the Digestive Disease Week in New Orleans independently confirmed that the effects of endoscopic radiofrequency ablation (RFA) for eradicating a pre-cancerous condition of the esophagus called Barrett's esophagus are durable in the long-term. In a plenary scientific presentation titled "Endoscopic Radiofrequency Ablation for Barrett's Esophagus: Five-year Durability Outcomes from a Prospective Multi-Center Trial," patients with Barrett's esophagus were treated with endoscopic RFA using the HALO system.

6 May 2010

Study on risk factors, potential harm associated with medication errors at hospital admission

A recent study conducted at Northwestern Memorial Hospital found that almost 50 percent of medication discrepancies were related to a failure to understand all of the prescription medications patients were taking at the time of hospital admission. While it's common for patients not to recall all of their medications, especially when they are not feeling well or being unexpectedly admitted to the hospital, the results can be serious.

6 May 2010

Patients Medical provides patients with valuable tips to prevent Lyme disease

Patients Medical, a leading integrative and holistic medical center in New York City, is supporting National Lyme Disease Awareness month by providing patients with valuable tips to prevent the disease, as well as education on the best treatment options available.

6 May 2010

RayBiotech announces biomarker grant winners

RayBiotech, Inc. has announced the winners of its Biomarker Discovery Pilot Grant program. In total, 18 award recipients were chosen for grants of up to $20,000 each, redeemable for RayBiotech products and services. "By offering these grants," states Dr. Ray (Ruopan) Huang, Founder and President of RayBiotech, "we intend to demonstrate that any researcher with a modest research budget can successfully discover and validate disease-related biomarkers using our antibody arrays."

6 May 2010

THI at St. Luke's awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure

Physician scientists at the Texas Heart Institute at St. Luke's Episcopal Hospital (THI at St. Luke's) have been awarded a grant of almost $1.5 million by the National Institutes of Health for research into treatments for patients with end-stage heart failure that would combine heart-assist devices and adult stem-cell treatments.

6 May 2010

Transplant News and Research

Clinical Data expands PGxHealth's FAMILION tests to include two new tests to diagnose heart diseases

Benefits outweigh risks in myeloablative therapy for children with high-risk neuroblastoma

NY public hospital system plans to lay off about 500 workers and other state news

DUSA Pharmaceuticals first-quarter total product revenues up 22%

New multicenter trial achieves 71% survival in AML children

Increased cholesterol levels can affect microenvironment of bone marrow

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

Steroids can raise cardiovascular risks in post-transplant patients

Inflammation enzyme regulates production of brown fat tissue

DUSA Pharmaceuticals receives notice of allowance for patent covering blue light technology

Movements of satellite cells could help patients with muscular dystrophy: MU researchers

Genzyme to initiate $2 billion stock buyback

Cytochroma reports positive results from Phase I trial for CTAP201 Injection in hemodialysis patients

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Vical reports net loss of $8.5 million for first-quarter 2010

Study confirms long-term durability of endoscopic RFA using HALO system for eradicating Barrett's esophagus

Study on risk factors, potential harm associated with medication errors at hospital admission

Patients Medical provides patients with valuable tips to prevent Lyme disease

RayBiotech announces biomarker grant winners

THI at St. Luke's awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News